12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LEE011: Phase III start

This month, Novartis will begin the double-blind, placebo-controlled, North American Phase III MONALEESA-2 trial to evaluate 600 mg oral LEE011 once daily for the first 3 weeks of a 4-week cycle in combination with 2.5 mg letrozole once...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >